New drug aims to stop CMV from coming back after transplant

NCT ID NCT06407232

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from coming back in kidney or kidney/pancreas transplant patients who are at high risk. About 90 adults will take letermovir daily for 84 days and be followed for 6 months. The goal is to see if it reduces the number of CMV flare-ups and the need for other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir (Prevymis)
What this could lead to: If successful, letermovir could offer a new way to prevent CMV from coming back after treatment in transplant patients, reducing the need for other antiviral drugs.
What could go wrong: This is a phase 3 trial with only 90 participants, so results may not apply to everyone. Letermovir may not work as well as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection pyelonephritis renal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTIONS KIDNEY TRANSPLANT INFECTION PANCREAS TRANSPLANT

Contacts and locations

Locations

UW Hospital and Clinics
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.